Roche Media News

FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer

4 days ago

Approval based on Phase III ALINA study showing Alecensa reduced the risk...

Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS

6 days ago

Results from the Phase III study showed that subcutaneous (SC) injection was...

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study

8 days ago

Columvi, in combination with chemotherapy, demonstrated a statistically significant improvement in overall...

Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis

12 days ago

The Elecsys® pTau217 plasma biomarker test is being developed as part of...

Roche receives FDA approval for the first molecular test to screen for malaria in blood donors

28 days ago

Roche Annual General Meeting 2024

about 1 month ago

All proposals of the Board of Directors approvedSeverin Schwan re-elected as Chairman...

Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when added to standard of care

about 2 months ago

KARDIA-2 study met its primary endpoint, demonstrating clinically significant systolic blood pressure...

New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies

about 2 months ago

Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with...

FDA approves Xolair as first and only medicine for children and adults with one or more food allergies

2 months ago

Approval is based on data from the NIH-sponsored Phase III OUtMATCH study...

New long-term data for Roche’s Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)

3 months ago

Vabysmo sustained robust drying of retinal fluid, often associated with distorted or...

[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline

3 months ago

Group sales grow by 1%1 at constant exchange rates (CER; -7% in...

European Commission approves Roche’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types

3 months ago

Subcutaneous (SC) injection offers the potential for a faster, more convenient alternative...